Aytu BioPharma (NASDAQ:AYTU) Rating Lowered to Sell at Zacks Investment Research

Aytu BioPharma (NASDAQ:AYTU – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company’s marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. “

AYTU has been the topic of a number of other reports. HC Wainwright reduced their target price on shares of Aytu BioPharma from $24.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, April 28th. Cantor Fitzgerald lowered their target price on shares of Aytu BioPharma from $11.00 to $5.00 in a research note on Tuesday.

Shares of NASDAQ:AYTU traded down $0.01 during trading on Thursday, reaching $0.54. 224,647 shares of the company were exchanged, compared to its average volume of 736,755. The firm has a market capitalization of $18.01 million, a PE ratio of -0.13 and a beta of -0.13. The business’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $1.34. Aytu BioPharma has a 12-month low of $0.45 and a 12-month high of $6.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.87 and a quick ratio of 0.71.

Aytu BioPharma (NASDAQ:AYTU – Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($1.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($1.38). Aytu BioPharma had a negative return on equity of 36.91% and a negative net margin of 120.24%. On average, sell-side analysts anticipate that Aytu BioPharma will post -1.85 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Aytu BioPharma by 15.1% during the first quarter. Renaissance Technologies LLC now owns 765,469 shares of the company’s stock valued at $827,000 after purchasing an additional 100,400 shares during the period. BlackRock Inc. lifted its position in Aytu BioPharma by 10.0% during the fourth quarter. BlackRock Inc. now owns 548,724 shares of the company’s stock valued at $741,000 after purchasing an additional 49,772 shares during the period. Marshall Wace LLP acquired a new position in Aytu BioPharma during the fourth quarter valued at $70,000. Morgan Stanley lifted its position in Aytu BioPharma by 793.5% during the third quarter. Morgan Stanley now owns 377,922 shares of the company’s stock valued at $1,088,000 after purchasing an additional 335,625 shares during the period. Finally, Geode Capital Management LLC lifted its position in Aytu BioPharma by 16.3% during the third quarter. Geode Capital Management LLC now owns 257,433 shares of the company’s stock valued at $741,000 after purchasing an additional 35,994 shares during the period. Institutional investors own 11.47% of the company’s stock.

About Aytu BioPharma (Get Rating)

Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.

Featured Articles